Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jaguar Animal Health ( (JAGX) ) has provided an announcement.
On September 30, 2025, Jaguar Health, Inc. entered into a privately negotiated exchange agreement with a holder of royalty interest, resulting in the issuance of 286,532 shares of common stock in exchange for a $600,000 reduction in the outstanding royalty interest balance. This strategic move highlights Jaguar Health’s efforts to manage its financial obligations and optimize shareholder value, potentially impacting its financial stability and market positioning.
The most recent analyst rating on (JAGX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
Jaguar Animal Health’s overall stock score is primarily impacted by its financial instability, characterized by high leverage and consistent losses. While there are positive signals from technical analysis and earnings call highlights, these are overshadowed by valuation concerns and financial performance challenges.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Jaguar Health, Inc. operates in the pharmaceutical industry, focusing on developing and commercializing gastrointestinal products for both human and animal health markets.
Average Trading Volume: 137,654
Technical Sentiment Signal: Sell
Current Market Cap: $4.85M
See more data about JAGX stock on TipRanks’ Stock Analysis page.